when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Antisense Oligonucleotide (ASO) · news · pharmadog

← back to Antisense Oligonucleotide (ASO)

News · Antisense Oligonucleotide (ASO)

61 stories

7dMilestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeatbiospace

12dRoche, Ionis RNA drug scores in kidney disease studybiopharma dive

12dRoche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nodbiospace

12dIonis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALSbiospace

12dRoche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease marketfiercebiotech

17dUltragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4Mbiospace

19dNovartis halts TREM2 targeting ALS program in 4th trial stumble in a monthbiospace

19d5 biotechs braving the commercial waters with product launchesbiospace

21dScholar Rock secures first FDA approval for muscle-targeting rare disease drugbiospace

24dNovartis drags peers down with triple asset stumblebiospace

24dNovartis drags peers down with triple asset failurebiospace

24dNovartis’ board faces investor scrutiny after M&A misfires and R&D flopsbiospace

26dNovo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander diseasebiospace

26dGV-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturingfiercebiotech

27dNovo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’biospace

27dNovartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappointsbiospace

27dNovartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizonsbiospace

28dNovartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lillyendpoints

Sep 4, 26Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trialfiercebiotech

Sep 4, 26STAT+: After failure of Angelman syndrome drug, experts see hope in other experimental therapiesstat

Sep 4, 26Ionis wins FDA approval of Alexander disease drug zilganersenendpoints

Sep 4, 26Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipelinefiercebiotech

Sep 3, 26FDA approves Ionis’ antisense drug as first targeted therapy for Alexander diseasebiospace

Sep 3, 26FDA Approves First Drug to Treat Alexander Diseasefda press

Sep 3, 26Ultragenyx’s 'high-risk' Angelman bet fails, cratering stock and forcing strategic reviewbiospace

Sep 3, 26Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’fiercebiotech

Sep 3, 26Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patientsendpoints

Aug 31, 26ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsybiopharma dive

Aug 31, 26ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CMfiercebiotech

Aug 31, 26Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts splitbiospace

← prevpage 1 of 3next →